SUNNYVALE, Calif., March 18 Arbor Vita Corporation (AVC),a privately held biotechnology company, today announced that Linda McAllister,M.D., Ph.D., has joined the company's management team as Vice President ofDiagnostics, a new position. Dr. McAllister has recent experience in the lifesciences and diagnostics industry as well as in clinical medicine and academicresearch, where her research focus included molecular genetics and DNAmicroarray applications in human genetics.
"We are delighted about Linda's decision to join Arbor Vita at this time,"commented Peter S. Lu, M.D., Founder, President and Chief Executive Officer."Linda brings to AVC an impressive record of accomplishments that will beinvaluable as she leads our diagnostic efforts. We believe that her grasp ofnew technologies combined with an understanding of the clinical practices andthe competitive market will position AVC to great advantage for ourdiagnostics business going forward."
Most recently, Dr. McAllister was Director of Technology Management atRoche Diagnostics, where she managed a portfolio of early-stage technologyopportunities. Previously, she was Director of Clinical Genetics at CeleraDiagnostics, where she negotiated access to and managed most of the clinicalstudy samples. Prior to Celera, Dr. McAllister was Program Manager ofGenotyping at Affymetrix, where she launched two products and is the inventoron a number of key patents. In addition to her business career, shesimultaneously served as Adjunct Clinical Professor in the Department ofMedicine at UCSF from 1992 to 2005. She received her B.S. in Biology andChemistry from the California Institute of Technology and both a Ph.D. inNeurosciences and an M.D. from Stanford University Medical School. Dr.McAllister completed her residency in Internal Medicine at UCSF and was aBugher Cardiovascular Research Fellow at Stanford under the direction of Drs.Victor Dzau, Patrick O. Brown and David Botstein. She is the author ofnumerous scientific publications and holds six patents.
"I am excited to be part of the Arbor Vita management team, and to helptranslate the company's elegant and powerful PDZ biology from research to theclinic," stated Linda McAllister, M.D., Ph.D. "The company is well poised torealize commercial success in the emerging field of personalized medicine, byleveraging its PDZ-enabling technology for both diagnostics and therapeutics.At Arbor Vita, I expect to continue my personal mission to improve healthcarethrough the delivery of novel technologies that have a positive impact onglobal health."
About Arbor Vita Corporation
Arbor Vita (http://www.arborvita.com) is a biotechnology company focusedon the discovery, development, and commercialization of novel drugs anddiagnostics addressing disease through a new family of targets, PDZ proteins.PDZ proteins are critical elements that organize and regulate many signalingpathways in human cells. Arbor Vita is pioneering the development of boththerapeutics and diagnostics through their unique understanding of the role ofPDZs in cell signaling and disease. The company is addressing major healthissues including cervical cancer, stroke and cardiovascular disease as well asinfectious diseases such as influenza.
SOURCE Arbor Vita Corporation